Findings seen for individuals undergoing revascularization after non-ST-segment elevation myocardial infarction ...

Extending wait time criteria from 1 to 3 hours after withdrawal of life-sustaining treatment for kidney donation after circulatory death (DCD) does not compromise kidney transplant outcomes and may ...

Investigators report a survival benefit with primary tumor ablation in patients with mRCC compared with no local treatment.

Mohammad Ali Sheffeh, MD, from the Mayo Clinic in Rochester, Minnesota, and colleagues examined the efficacy of GLP-1 RA or SGLT-2i initiation for reducing mortality or cardiovascular events among ...

(HealthDay News) — There is a small inverse association between plasma omega-6 and omega-3 polyunsaturated fatty acids (PUFAs) and cancer, according to a study published online in the International ...

Preclinical studies have shown AT-02 is able to bind to multiple amyloid types and can induce macrophage mediated amyloid phagocytosis and removal. The Food and Drug Administration has granted Orphan ...

GLP-1RA drugs and SGLT2 inhibitors were associated with a lower risk for nonalcoholic fatty liver disease among individuals with type 2 diabetes.

Fasting shows benefits compared with eating meals or snacks at night. (HealthDay News) — Fasting at night prevents impairments in glucose tolerance among simulated night-shift work, according to a ...

Supply chain issues are more likely to result in drug shortages in the United States than in Canada, data suggest.

SGLT2 inhibitors and GLP-1 receptor agonists exhibit renoprotective effects in patients with CKD with and without diabetes.

SGLT2 inhibitors may help reduce the risk of nephrolithiasis in patients with type 2 diabetes, including those with co-existing gout. Recent large-scale studies support that sodium-glucose ...

Drugs for diabetic kidney disease treatment have greatly expanded, allowing research and consensus on their optimal use.